Category Archives: ClinAccel.Net

FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe

Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of that region: Bulgaria, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation, and the Ukraine (listed alphabetically). The … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, FDA | Leave a comment

ARREST Phase IIb Top-Line 52 weeks results

Below, we are re-publishing with permission the press-release issued by Galmed Pharmaceuticals Ltd. on the 12th of June 2018 Galmed’s 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator | Leave a comment

Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, Conferences | Leave a comment

Clinical Accelerator announces collaboration with VisCardia for investigating a novel device therapy for chronic heart failure

Kiev, Ukraine – December 11, 2017: Clinical Accelerator, a full-service clinical contract research organization, is pleased to announce it has entered into a collaboration with VisCardia Inc. for conducting clinical studies for its VisONE medical device in the Ukraine. The … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator | Leave a comment

Referring physicians: the overlooked resource for faster patient enrolment

It is widely known and understood that the no. 1 cause of delays in clinical trials is inefficient patient enrolment. The problem has become widespread and does not show any signs of abating. According to a TUFTS analysis, 48% of … Continue reading

Posted in ClinAccel.Net, Clinical Accelerator, Cost of Clinical Trials, Patient Enrolment | Leave a comment